Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Given COVID-19, is there a good hypofractionated regimen for postmastectomy radiation for locally advanced breast cancer?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Abramson Cancer Center, University of Pennsylvania

In light of COVID-19, we offer 2.66 x 16 PMRT with comprehensive RNI. This regimen is under study in ALLIANCE A221505, commonly known as RT-CHARM. Primary endpoint is reconstruction complications at 2 years. We discuss with reconstructed patients (most all will take if offered). Routinely given to u...

Would you offer hippocampal sparing whole brain radiation for patients with brain metastases due to ES-SCLC?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Karmanos Cancer Institute - McLaren Proton Therapy Center

Until we have built-in auto-segmentation, I find the RTOG contouring atlas very helpful for manual contouring of the hippocampus. I tend to use the lateral ventricle as my main landmark, and look for the circle of gray matter located medial to it. Once I've drawn a hippocampus, I'll look at it in th...

Do you recommend chemoradiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?

1
4 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

Tough question, with lots of evolution in this area in the past few years. The data would suggest that for borderline resectable pancreatic cancer, there is a benefit in terms of OS from preoperative treatment. For unresectable disease, the small chance of conversion into resectability is worth the ...

How long after achieving a CR would you consider stopping pembrolizumab in metastatic melanoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Institut Gustave Roussy

Based on Keynote 001 and more recently on Keynote 006, where we observed sustained remission in more than 90% of the patients who had stopped pembrolizumab for complete response, we usually consider stopping pembrolizumab in patients who have a confirmed complete response (this means that we have tw...

What would be the approach for radiation treatment of sarcoma of a finger?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

The correct approach for definitive management is an amputation or perhaps, if possible, a digit-sparing resection with preoperative RT. As always, the crux with organ-sparing approaches is that we need to leave an organ that is both disease free and functional, and I am skeptical that definitive-in...

For locally advanced breast cancer, to what dose do you treat undissected clinically positive level III axilla, SCV or IM nodes?

23
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

At MD Anderson Cancer Center, we systematically stage the regional nodes using ultrasound. We biopsy suspicious nodes with FNA at the time of ultrasound. Given this systematic approach to staging, we have a large experience treating patients with biopsy-confirmed infraclavicular, supraclavicular, an...

How do you treat a focal pericardial metastasis?

1
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Quillen VA Medical Center

In the era of oligometastatic disease, I understand the question. But an isolated event found at the pericardium is a stretch of concept. The issues of both the target and its physiological motion, and the presumably late cardiac injury, balance a choice of what’s best for the patient. How likely is...

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

3
4 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...

Can the addition of posterior axillary boost (PAB) for breast cancer increase the risk of brachial plexopathy?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

In the era of 3D volume based planning, it is important to contour the nodal regions and optimize coverage to the volume. In the 2D era, people use to prescribe to mid axilla and a PAB was commonly used. We know now that axillary nodes are far more anterior then that. To cover these nodes, we use an...

When treating the whole brain with hippocampal avoidance, do you ever deliver SIB to gross disease?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northwestern Medicine Cancer Center Warrenville

There have been several papers and an ongoing trial evaluating the safety and efficacy of including SIB to macrometastatic disease with HA-WBRT. A recently published trial from the UT-Southwestern team was a single-arm phase II trial, which treated 50 brain metastasis patients with HA-WBRT to 20 Gy ...